M A Socinski

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 5:1963-9. 2010
  2. ncbi Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition)
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599, USA
    Chest 132:277S-289S. 2007
  3. ncbi Limited-stage small-cell lung cancer: the current status of combined-modality therapy
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Clin Oncol 25:4137-45. 2007
  4. ncbi Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, Multidisciplinary Thoracic Oncology Program, University of North Carolina at Chapel Hill, Chapel Hill 27599, USA
    J Clin Oncol 24:4840-7. 2006
  5. ncbi Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Clin Cancer Res 13:s4597-601. 2007
  6. ncbi The emergence of a unique population in non-small cell lung cancer: systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy
    Mark A Socinski
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Semin Oncol 33:S32-8. 2006
  7. ncbi Seeking new options for the treatment of small-cell lung cancer
    M A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Lung Cancer 50:S25-6. 2005
  8. ncbi A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer
    M A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Ann Oncol 17:104-9. 2006
  9. ncbi Duration of therapy in advanced, metastatic non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    Clin Adv Hematol Oncol 1:33-8. 2003
  10. ncbi Combined modality trials in unresectable stage III non-small cell lung cancer: the Cancer and Leukemia Group B experience
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of South Carolina, 101 Manning Drive, Chapel Hill, NC 27599, USA
    Semin Oncol 32:S114-8. 2005

Detail Information

Publications87

  1. ncbi Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 5:1963-9. 2010
    ..This trial assessed pemetrexed-carboplatin ± enzastaurin to docetaxel-carboplatin in advanced non-small cell lung cancer...
  2. ncbi Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition)
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599, USA
    Chest 132:277S-289S. 2007
    ..Stage IV non-small cell lung cancer (NSCLC) remains a treatable but incurable disease...
  3. ncbi Limited-stage small-cell lung cancer: the current status of combined-modality therapy
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Clin Oncol 25:4137-45. 2007
    ..LS-SCLC has been a model cancer in terms of the potential benefit of combined chemoradiotherapy strategies in improving patient outcomes...
  4. ncbi Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, Multidisciplinary Thoracic Oncology Program, University of North Carolina at Chapel Hill, Chapel Hill 27599, USA
    J Clin Oncol 24:4840-7. 2006
    ....
  5. ncbi Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Clin Cancer Res 13:s4597-601. 2007
    ..The lack of a biomarker to identify a subset of NSCLC patients who may derive benefit from this agent limits any potential enthusiasm for further trials of panitumumab at this time in NSCLC...
  6. ncbi The emergence of a unique population in non-small cell lung cancer: systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy
    Mark A Socinski
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Semin Oncol 33:S32-8. 2006
    ....
  7. ncbi Seeking new options for the treatment of small-cell lung cancer
    M A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Lung Cancer 50:S25-6. 2005
    ..Observations from this trial will help to define the future role of pemetrexed in SCLC...
  8. ncbi A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer
    M A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Ann Oncol 17:104-9. 2006
    ..The optimal schedule of taxane administration has been an area of active interest in several recent clinical trials...
  9. ncbi Duration of therapy in advanced, metastatic non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    Clin Adv Hematol Oncol 1:33-8. 2003
    ..Prolonged therapy does not appear to improve survival and carries the risk of cumulative toxicity. Second-line therapy considered in those patients fit enough to receive it at the time of disease progression...
  10. ncbi Combined modality trials in unresectable stage III non-small cell lung cancer: the Cancer and Leukemia Group B experience
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of South Carolina, 101 Manning Drive, Chapel Hill, NC 27599, USA
    Semin Oncol 32:S114-8. 2005
    ..In addition, a change in the therapeutic platform is planned that explores a full-dose systemic approach with the antifolate pemetrexed that possesses radiosensitizing properties...
  11. ncbi Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599, USA
    J Clin Oncol 26:650-6. 2008
    ....
  12. ncbi Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, NC 27599, USA
    J Clin Oncol 26:2457-63. 2008
    ..To evaluate 74 Gy thoracic radiation therapy (TRT) with induction and concurrent chemotherapy in stage IIIA/B non-small-cell lung cancer (NSCLC)...
  13. ncbi The current status and evolving role of sunitinib in non-small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:S119-23. 2008
    ..Results of these trials are eagerly awaited and will help define the role of sunitinib in the therapeutic approach to NSCLC...
  14. ncbi A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Thorac Oncol 5:852-61. 2010
    ..This nonrandomized study aimed to identify the optimal dose of every-3-week (q3w) and weekly nab-paclitaxel plus q3w carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) for a phase 3 trial...
  15. ncbi The emerging role of biomarkers in advanced non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Clin Lung Cancer 11:149-59. 2010
    ..Further assessment of these and other novel biomarkers is warranted to help define which patients with advanced NSCLC may derive the most benefit from targeted therapies...
  16. ncbi Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Thorac Oncol 5:354-60. 2010
    ....
  17. ncbi Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 27:5255-61. 2009
    ..This phase II trial, AVF3752g (PASSPORT), specifically addressed bevacizumab safety (incidence of grade > or = 2 CNS hemorrhage) in patients with NSCLC and previously treated brain metastases...
  18. ncbi Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    J Clin Oncol 27:4787-92. 2009
    ....
  19. ncbi A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)
    M A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Ann Oncol 20:1068-73. 2009
    ..This trial investigated the efficacy and safety of weekly cetuximab combined with two different schedules of paclitaxel/carboplatin for stage IIIB/IV non-small-cell lung cancer (NSCLC)...
  20. ncbi Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial
    Mark A Socinski
    University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:1308-16. 2008
    ..We undertook a phase II trial to assess the efficacy and safety of single-agent pemetrexed (P) in relapsed small-cell lung cancer (SCLC) patients...
  21. ncbi Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Drugs Today (Barc) 44:293-301. 2008
    ..Bevacizumab is the first targeted therapeutic agent to improve survival in advanced NSCLC when added to standard chemotherapeutic regimens...
  22. ncbi Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer
    Mark A Socinski
    University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    Cancer Treat Rev 37:611-7. 2011
    ..g., sorafenib, sunitinib) and triple (e.g., BIBF 1120, pazopanib) antiangiogenic tyrosine kinase inhibitors currently in development for the treatment of non-small cell lung cancer...
  23. ncbi Chemotherapeutic issues in the management of unresectable stage III non-small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of South Carolina, 101 Manning Drive, Chapel Hill, NC 27599, USA
    Semin Oncol 32:S18-24. 2005
    ..Future aggressive approaches must enhance both locoregional and distant control of occult disease, with acceptable rates of both acute and long-term toxicities...
  24. ncbi Adjuvant therapy of resected non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Clin Lung Cancer 6:162-9. 2004
    ..Currently, the totality of the data supports a discussion with patients with resected NSCLC regarding the potential benefits of adjuvant therapy...
  25. ncbi Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 22:4341-50. 2004
    ..Dose escalation using three-dimensional thoracic conformal radiation therapy (TCRT) is one strategy to improve local control and perhaps survival...
  26. ncbi Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity
    M A Socinski
    Cancer and Leukemia Group B, Chicago, IL, USA
    Ann Oncol 15:1033-41. 2004
    ..Combined modality therapy (CMT) is the standard of care for patients with unresectable stage III non-small-cell lung cancer (NSCLC); however, insufficient data are available regarding prognostic factors in this disease setting...
  27. ncbi Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    J Clin Oncol 20:1335-43. 2002
    ..To compare four cycles of therapy versus continuous therapy to determine the optimal duration of chemotherapy in advanced non-small-cell lung cancer (NSCLC)...
  28. ncbi Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Cancer 95:1265-73. 2002
    ..The authors sought to determine the activity of second-line, low-dose, weekly paclitaxel in patients with NSCLC who failed first-line chemotherapy with carboplatin plus paclitaxel...
  29. ncbi Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Cancer 95:1520-7. 2002
    ..This Phase II multicenter, open-label, single-arm study evaluated the efficacy and safety of a three-drug combination of irinotecan (CPT-11), paclitaxel, and carboplatin in advanced nonsmall cell lung carcinoma (NSCLC)...
  30. ncbi Chemotherapeutic management of stage IV non-small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, CB 7305, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Chest 123:226S-243S. 2003
    ..In addition, this awareness will allow them to make referrals, when appropriate, to physicians who are trained in the administration of chemotherapy and the management of patients undergoing such therapy...
  31. ncbi Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, and US Oncology, Houston, TX, USA
    Lung Cancer 40:91-7. 2003
    ..This regimen has a tolerable toxicity profile and a favorable and convenient administration schedule...
  32. ncbi The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, CB 7305, 3009 Old Clinic Building, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7305, USA
    Respir Care Clin N Am 9:207-36. 2003
    ..It is only through the successful and timely completion of well-designed clinical trials that we will advance our knowledge of improved treatment options for our patients with this disease...
  33. ncbi Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill 27599 7305, USA
    Clin Lung Cancer 5:274-89. 2004
    ..Trials under way will determine the future of adjuvant or induction chemotherapy in treating this patient population...
  34. ncbi Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Clin Cancer Res 10:4210s-4214s. 2004
    ..Future research may improve outcomes through identifying prognostic markers of treatment response to both standard cytotoxic and newer "targeted" therapies...
  35. ncbi Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer
    M A Socinski
    The Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill 27599, USA
    Oncologist 4:408-16. 1999
    ..Given the overall activity and impact on survival along with an acceptable toxicity profile, single-agent paclitaxel warrants comparison to other active agents and combination regimens in advanced, metastatic NSCLC...
  36. ncbi Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer
    M A Socinski
    Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, NC 27599, USA
    J Clin Oncol 19:1078-87. 2001
    ..To determine the maximum-tolerated dose, toxicities, and dose suitable for phase II/III trials of irinotecan (CPT-11) combined with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer (NSCLC)...
  37. ncbi Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial
    M A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill 27599, USA
    Cancer 92:1213-23. 2001
    ..The dose of thoracic conformal radiation therapy (TCRT) from 60 to 74 gray (Gy) was increased. Endpoints included response rate, toxicity, and survival...
  38. ncbi Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium
    M A Socinski
    Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27514, USA
    Oncologist 6:20-4. 2001
    ..Key morbidity observed thus far has involved the esophagus. Further cohorts of patients will receive higher doses of conformal radiotherapy (in 6.4 Gy increments) until the maximum tolerated dose is reached...
  39. ncbi Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial
    Jean Yves Douillard
    M D Anderson Cancer Center, Thoracic Head and Neck Medical Oncology, Box 432, 1515 Holcombe Blvd, Houston, TX 77401, USA
    J Clin Oncol 28:744-52. 2010
    ....
  40. ncbi Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer
    Thomas A Hensing
    Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
    Lung Cancer 47:253-9. 2005
    ..Factors increasing the likelihood of second-line therapy include high performance status, female gender and non-squamous histology, while early termination of first-line therapy decreased the likelihood of further therapy...
  41. ncbi Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance
    Jyoti D Patel
    Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Clin Lung Cancer 10:252-6. 2009
    ....
  42. ncbi Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium
    Lawrence B Marks
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 22:4329-40. 2004
    ..6 Gy bid) for unresectable locally advanced lung cancer (IIB to IIIA/B) following induction carboplatin/paclitaxel (C/T) or carboplatin/vinorelbine (C/N)...
  43. ncbi A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer
    Heidi H Gillenwater
    The Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Cancer Invest 23:511-9. 2005
    ..The purpose of this Phase I trial was to determine the maximally tolerated systemic exposure (MTSE) of topotecan in combination with carboplatin and etoposide...
  44. ncbi The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel
    Thomas A Hensing
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    Cancer 98:779-88. 2003
    ....
  45. ncbi Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill 27599-7305, USA
    Clin Lung Cancer 7:S111-7. 2006
    ..Well-designed clinical trials with appropriate patient selection, as well as continued efforts in translational research and pharmacogenomics, are crucial for progress in this disease...
  46. ncbi Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
    Edward S Kim
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Lancet 372:1809-18. 2008
    ..We compared gefitinib with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who had been pretreated with platinum-based chemotherapy...
  47. ncbi Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy
    Carrie B Lee
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27599, USA
    Clin Lung Cancer 8:195-202. 2006
    ..Further well-designed clinical trials that examine RT dose escalation, improved tumor targeting, altered fractionation, and incorporation of biologic agents are crucial for progress in this disease...
  48. ncbi Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors
    Thomas E Stinchcombe
    Department of Hematology Oncology, Developmental Therapeutics Group Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
    Cancer Chemother Pharmacol 60:759-66. 2007
    ..The purpose of this study was to determine the maximum tolerated dose (MTD) of ABI-007, on three different schedules in combination with carboplatin...
  49. ncbi Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials
    Carrie B Lee
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Rev Recent Clin Trials 2:117-20. 2007
    ..The data from these trials suggest that optimal use of anti-angiogenic agents in NSCLC is more likely in combination with standard cytotoxic agents, however the most effective combination with the least toxicity is yet to be determined...
  50. ncbi Current and evolving treatment options for limited stage small cell lung cancer
    Carrie B Lee
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Curr Opin Oncol 18:162-72. 2006
    ..Targeted therapies and advances in the radiotherapy technological aspects represent opportunities for improved outcomes in the future management of this aggressive disease...
  51. ncbi Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation
    Shannon K Penland
    Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA
    Semin Radiat Oncol 14:326-34. 2004
    ..This article will review the current data regarding treatment of this heterogeneous group of patients. In addition, a brief summary of new molecular therapies and chemotherapeutics will be presented...
  52. ncbi Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing
    A Donahue
    University of North Carolina, University of Washington, CB #7360, Beard Hall, Box 357630, Chapel Hill, NC 27599-7360 Seattle, WA 98195, USA
    Cancer Chemother Pharmacol 47:373-9. 2001
    ..The greater negative bias found for the latter three estimates of carboplatin clearance could result in underdosing of carboplatin...
  53. ncbi The evolving role of pemetrexed (Alimta) in lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Semin Oncol 32:S16-22. 2005
    ..A phase II trial of single-agent pemetrexed is under way in both sensitive- and refractory-relapsed small cell lung cancer. Given the activity and excellent tolerability of pemetrexed, further studies in lung cancer are warranted...
  54. ncbi Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer
    Stacy S Shord
    School of Pharmacy, CB #7360, Beard Hall, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Cancer Chemother Pharmacol 51:328-36. 2003
    ..05). CONCLUSIONS: Gemcitabine plasma pharmacokinetic parameters are significantly altered in the presence of paclitaxel...
  55. ncbi Pemetrexed (Alimta) in small cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Semin Oncol 32:S1-4. 2005
    ..Also, preliminary data indicates that full doses of carboplatin/pemetrexed can be administered with thoracic radiation therapy, supporting a future clinical trial initiative in LS-SCLC...
  56. ncbi Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer
    Everett E Vokes
    Section of Hematology Oncology, Department of Medicine, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637 1470, USA
    Clin Cancer Res 11:5045s-5050s. 2005
    ..Currently ongoing trials involving novel approaches are reviewed here...
  57. ncbi Radiation-induced sarcoma after high-dose thoracic radiation therapy in non-small-cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
    J Clin Oncol 25:1621-3. 2007
  58. ncbi Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Thorac Oncol 2:819-26. 2007
    ..Physicians' beliefs and practice patterns may differ significantly from established guidelines. We conducted a survey to assess and compare physician beliefs against the evidence-based guidelines...
  59. ncbi Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Clin Oncol 24:407-12. 2006
    ..We investigated whether the disparity in survival would persist when patients were treated with similar therapies (ie, phase II/III Cancer and Leukemia Group B [CALGB] trials)...
  60. ncbi Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer
    M Patricia Rivera
    Multidisciplinary Thoracic Oncology Group, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7248, USA
    Chest 135:1588-95. 2009
    ....
  61. ncbi Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:521-6. 2008
    ..This trial was designed to determine the maximum tolerated dose and dose limiting toxicities (DLT) of nab-paclitaxel in combination with gemcitabine...
  62. ncbi High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial
    Julian G Rosenman
    Department of Radiation Oncology, Lineberger Comprehensive Cancer Center of the University of North Carolina University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA
    Int J Radiat Oncol Biol Phys 54:348-56. 2002
    ..The median survival of 24 months, 3-year survival rate of 38%, and the high dose of radiation used justified a critical analysis of the technical and clinical components of this trial...
  63. ncbi A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program at Lineberger Comprehensive Cancer Center at the University of North Carolina, Physicians Office Building, 3rd Floor 170 Manning Drive, CB 7305, Chapel Hill, NC 27599 7305, USA
    Cancer Invest 28:208-15. 2010
    ..To investigate the activity of carboplatin and cetuximab in NSCLC. Patients and Methods: This was a single arm, multicenter phase II trial, and the primary objective was response rate...
  64. ncbi Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy
    Thomas E Stinchcombe
    Department of Hematology Oncology, University of North Carolina, Chapel Hill NC 27599 7305, USA
    Lung Cancer 52:67-74. 2006
    ..To evaluate the influence of clinical covariates, particularly pre-chemotherapy gross tumor volume (GTV), post-chemotherapy GTV, on overall survival in the treatment of stage III non-small cell lung cancer (NSCLC)...
  65. ncbi Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer
    Carrie B Lee
    Division of Hematology Oncology, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill, North Carolina, USA
    J Thorac Oncol 4:74-9. 2009
    ..Dose escalation of radiotherapy is one strategy used to improve locoregional control and survival, but it increases the risk of both early and late treatment related toxicities...
  66. ncbi Seeking a home for a PET, part 3: Emerging applications of positron emission tomography imaging in the management of patients with lung cancer
    Frank C Detterbeck
    Division of Cardiothoracic Surgery, Medical School Wing C Room 354, CB 7065, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7065, USA
    Chest 126:1656-66. 2004
    ..Further technologic improvements in PET scanners are likely to bring further benefits to the management of patients with lung cancer in the future...
  67. ncbi Current treatments for advanced stage non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Proc Am Thorac Soc 6:233-41. 2009
    ..Despite the improvements in care and number of therapeutic agents available, the survival for patients with advanced-stage NSCLC remains modest; novel approaches are required and participation in clinical trials should be encouraged...
  68. ncbi Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, 3009 Old Clinic Building CB 7305, Chapel Hill, NC 27599 7305, USA
    J Thorac Oncol 3:250-7. 2008
    ..We investigate the tolerability of gefitinib in combined modality therapy in combination with three-dimensional thoracic conformal radiation therapy (3-dimensional TCRT)...
  69. ncbi Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Patrick J Roberts
    Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 28:4769-77. 2010
    ....
  70. ncbi Lung cancer presenting with a solitary colon metastasis detected on positron emission tomography scan
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Clin Oncol 24:4939-40. 2006
  71. ncbi Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts
    D Neil Hayes
    University of North Carolina, Lineberger Comprehensive Cancer Center, CB 7295, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 24:5079-90. 2006
    ..Published reports suggest that DNA microarrays identify clinically meaningful subtypes of lung adenocarcinomas not recognizable by other routine tests. This report is an investigation of the reproducibility of the reported tumor subtypes...
  72. ncbi Combined modality therapy for stage III non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 11:809-23. 2006
    ..Thus, continued development and participation in clinical trials is crucial to further improvements in the treatment of patients with stage III disease...
  73. ncbi Maintenance therapy in advanced non-small cell lung cancer: current status and future implications
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Thorac Oncol 6:174-82. 2011
    ....
  74. ncbi Bevacizumab in the treatment of non-small-cell lung cancer
    T E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, Chapel Hill, NC 27599 7305, USA
    Oncogene 26:3691-8. 2007
    ..Attempts to identify surrogate markers of antiangiogenesis activity are currently ongoing, and may assist in the selection of patients for antiangiogenesis therapy and the development of this class of agents...
  75. ncbi A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer
    Heidi H Gillenwater
    Department of Hematology Oncology, University of Virginia Health Services, 6th Floor Multistory Building, Room 6007, Charlottesville, VA 22908, USA
    Lung Cancer 47:413-9. 2005
    ....
  76. ncbi Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status
    Thomas E Stinchcombe
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Lung Cancer 51:237-43. 2006
    ....
  77. ncbi Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer
    Frank C Detterbeck
    Division of Cardiothoracic Surgery, Department of Surgery, Members of the Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, NC, USA
    Chest 125:2300-8. 2004
    ..It is unclear and controversial whether a biopsy is needed in patients with clinical stage II lung cancer who have no PET uptake in the mediastinum...
  78. ncbi Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane)
    David Cella
    Center on Outcomes, Research and Education CORE, Evanston Northwestern Healthcare, and Northwestern University, Evanston, Illinois 60201, USA
    Cancer 98:822-31. 2003
    ..Cancer chemotherapy with some of the taxane class of agents can be associated with significant neurotoxicity, arthralgias, myalgias, and skin changes that may offset the therapeutic benefits of taxane use...
  79. ncbi Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer
    Frank C Detterbeck
    Yale Comprehensive Cancer Center, Yale University, New Haven, Connecticut 06520 8062, USA
    J Thorac Oncol 3:37-45. 2008
    ..Surgical resection alone remains suboptimal for patients with early-stage (I or II) non-small cell lung cancer. Two similar randomized phase II trials were conducted to define an active preoperative regimen in this disease state...
  80. ncbi Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901
    Stephen L Graziano
    State University of New York Upstate Medical University, Syracuse, New York 13210, USA
    J Thorac Oncol 3:158-62. 2008
    ..3 months. Because of these promising results, this dose and schedule of paclitaxel was evaluated in patients with ES-SCLC...
  81. ncbi Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis
    Maria Q Baggstrom
    Division of Medical Oncology, Washington University, St Louis, Missouri 63110, USA
    J Thorac Oncol 2:845-53. 2007
    ..To estimate the efficacy of third-generation (3G) chemotherapy agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, and irinotecan) on response and survival in stage IIIB/IV non-small cell lung cancer (NSCLC)...
  82. ncbi Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer
    Rogerio Lilenbaum
    Mount Sinai Cancer Center, Miami Beach, FL 33140, USA
    J Clin Oncol 24:4825-32. 2006
    ..This multicenter, phase II, randomized trial investigated efficacy and safety of irinotecan and docetaxel and irinotecan and gemcitabine, with or without CBX, in second-line treatment of NSCLC...
  83. ncbi Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer
    Thomas A Hensing
    Kellogg Cancer Center, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    Anticancer Drugs 17:697-704. 2006
    ..The lack of activity in either patient subgroup, however, does not support further evaluation of this drug as a single agent in this disease...
  84. ncbi Seeking a home for a PET, part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses
    Frank C Detterbeck
    Division of Cardiothoracic Surgery, Department of Surgery, University of North Carolina at Chapel Hill, USA
    Chest 125:2294-9. 2004
    ....
  85. ncbi Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer
    Mary E R O'Brien
    Royal Marsden Hospital, London, United Kingdom
    J Thorac Oncol 3:728-34. 2008
    ..Paclitaxel poliglumex (PPX), a macromolecular polymer-drug conjugate of paclitaxel and poly-l-glutamic acid, may enhance the therapeutic index of paclitaxel...
  86. ncbi A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer
    Thomas E Stinchcombe
    Department of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Lung Cancer 52:305-11. 2006
    ..The role of double agent therapy in this patient population is an area of investigation...
  87. ncbi Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer
    Corey J Langer
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Thorac Oncol 3:623-30. 2008
    ....